Overview

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Status:
Completed

Trial end date:
2019-12-09

Target enrollment:

Participant gender:

Summary

This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB11 compared to Lucentis® in subjects with neovascular AMD.

Phase:

Phase 3

Details

Lead Sponsor:

Samsung Bioepis Co., Ltd.

Treatments:

Ranibizumab